Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

von Hippel-Lindau Disease 1Triple Negative Breast Neoplasms 1Thyroid cancer, follicular 1Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Pheochromocytoma 1Paraganglioma 1Melanoma 1Hereditary leiomyomatosis and renal cell cancer 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Adenoma, Oxyphilic 1Adenocarcinoma, Follicular 1

Interventions

Magnetic Resonance Spectroscopy 9Iodine-131 7Thyrotropin Alfa 5trametinib 3lenvatinib 3cabozantinib 3Sunitinib 3Specimen Handling 3Fluorodeoxyglucose F18 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3vandetanib 2dabrafenib 2X-Rays 2Trastuzumab 2Sorafenib 2Rosiglitazone 2Radiotherapy 2Interviews as Topic 2Gefitinib 2Everolimus 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1tremelimumab 1tipifarnib 1tanespimycin 1spartalizumab 1selpercatinib 1sargramostim 1romidepsin 1pembrolizumab 1pazopanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma, Follicular × spartalizumab × Endocrine × Clear all
NCT04544111 2025-10-07

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
19 enrolled
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenoma, Oxyphilic, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡